TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)

NCT02378662 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision of the Early Termination of the study.

Conditions

Anemia of End Stage Renal Disease

Interventions

BIOLOGICAL: MDGN201 TARGTEPO

Sponsor

Aevi Genomic Medicine, LLC, a Cerecor company

Collaborators

[object Object]